aTyr Pharma Inc
NASDAQ:ATYR
aTyr Pharma Inc
Income from Continuing Operations
aTyr Pharma Inc
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
aTyr Pharma Inc
NASDAQ:ATYR
|
Income from Continuing Operations
-$63.8m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-10%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Income from Continuing Operations
$4.3B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Income from Continuing Operations
$479m
|
CAGR 3-Years
-57%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
-28%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Income from Continuing Operations
$4.1B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Income from Continuing Operations
-$535.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
3%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Income from Continuing Operations
$4.4B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
16%
|
CAGR 10-Years
29%
|
|
aTyr Pharma Inc
Glance View
aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel immunological pathways. The company is headquartered in San Diego, California and currently employs 49 full-time employees. The company went IPO on 2015-05-07. Its therapeutic candidate pipeline includes efzofitimod (ATYR1923), ATYR2810, NRP2 mAbs, AARS-1 and DARS-1. The ATYR1923, is a fusion protein comprised of the immunomodulatory domain of histidyl-tRNA synthetase fused to the fragment crystallizable (Fc) region of a human antibody and serves as a selective modulator of NRP2 that downregulates innate and adaptive immune response in inflammatory disease states. The firm is also developing efzofitimod as a potential disease-modifying therapy for patients with fibrotic lung diseases with high unmet medical need. ATYR2810 is a fully humanized monoclonal antibody that specifically and functionally blocks the interaction between NRP2 and one of its primary ligands VEGF. ATYR2810 is in preclinical development for the potential treatment of certain aggressive cancers where NRP2 is implicated.
See Also
What is aTyr Pharma Inc's Income from Continuing Operations?
Income from Continuing Operations
-63.8m
USD
Based on the financial report for Sep 30, 2024, aTyr Pharma Inc's Income from Continuing Operations amounts to -63.8m USD.
What is aTyr Pharma Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-10%
Over the last year, the Income from Continuing Operations growth was -48%. The average annual Income from Continuing Operations growth rates for aTyr Pharma Inc have been -28% over the past three years , -22% over the past five years , and -10% over the past ten years .
You don't have any saved screeners yet